The Rise of Germline Science - Human DNA Modification


Genetic modification of human DNA to correct disease causing code has long been a stated goal of medical science. Ever since the discovery of the double helix has man dreamed of understanding the inner workings of its own self, at its very core. The successful mapping of our genome took us closer to that universally acknowledged ambition. Time has not stood still since then nor has science strayed yet from its intended course. The rapid expansion of practical applications for genetics addressed to medical needs is a testament to the pursuit of that knowledge for good. In time there will be more progress and deeper understanding of the impact changes to our code will have - in the meantime research must continue apace and the wings of discovery allowed to extend outwards.     

My perspective on extending genetic research to germ line DNA editing is in line with the recent guidance from the International Society for Stem Cell Research (ISSCR). 

Rather than positioning early, and perhaps prematurely, the ongoing conversation is best taken forward with open engagement and presentation of additional scientific data, as it becomes available. Without additional ethical germline research, supported by industry & regulators, the topic of whether there is reason for undue concern cannot be fully addressed scientifically, apart from debating the broader question of should we (which is conditional imo). To reach any natural conclusion will take time and further industry wide clinical application of non-germline editing technologies, acceptance of less invasive genetic modification technologies, such as mitochondrial transfer, and the implementation of other embryo technologies for human benefit. 

An observation that underlies the issue is perhaps the historical fear factor effect of the "dual-use dilemma." That is to say the mere fact that there exists a possibility of misuse of scientific discoveries has in the past created significant barriers to progress and inhibited otherwise important developments in the timely advancement of research efforts to eradicate human disease & suffering.  Human cloning wasn't on the agenda when Dolly was born, however the realization that SCNT technology had a possible "dual-use" potential has hobbled otherwise beneficial therapeutic sources for ES cells. The entire field of "embryo" science has itself been caught up in an unproductive polarization issue of creation, life & intervention for cell science application. Even today only a very small percentage of the public actually know science is able to establish ES cell lines across all "embryo" technologies in a non-destructive ethical manner for personal & universal cellular treatments. This generally needs to be factored in when discussing the topic as it's unethical in itself not to address the fundamental reasons for many objections to "embryo" science and how it has clouded the perspective of delivering solutions to those in need. Solutions need to be sought, compromise established & educational outreach in the mass media targeted to this very point to end the divisiveness. This germline debate presents an ideal opportunity for such rapprochement.

How is early genetic modification of DNA at the germ/embryo stage going to be any different than the hES cell source miscues of the past unless the rhetoric of the applied technological benefit conversations reflect the lessons learned? 








Getting ahead of the issue is important, as it is with all emerging technological innovations that involve health. However, ensuring the safe sector development of recombinant DNA isn't the same as the ethical impact of human cloning, creating tens of millions+ supernumerary IVF embryos, engineering synthetic eggs/sperm & embryos, conducting germ line editing for disease or introducing DNA species' enhancements et al. These topics aren't challenges for science to overcome alone, they are fundamentally moral & ethical questions of benefit and use. They require careful scientific study, presentation in an open forum (not pay walled), thoughtful inclusive dialogue, education and public outreach.

Perhaps Leadership should suggest specific beneficial goals and propose a working version of a current dual use limitation charter when addressing the issue in the public framework. This will enable the field and public to express themselves within a clearly defined yet productive manner - i.e. what is potentially acceptable to Leadership and what isn't at this stage. Otherwise I can see the conversation repeating itself along the same lines as the media spin of scientific hyper reporting for readership numbers & incorrect assumptions of SCNT=human cloning, which was & still is an acknowledged no-go area in embryonics. Remember this concern set the tone for almost 20 years now of fallout in the field, not as a result of any specific efforts to progress human cloning but for the open door it presented. This was irrespective of the inherent scientific value in autologous ES cells & the sound pursuit of careful research driven embryo based technologies.


History has presented a number of important dual use dilemmas over the course of human history, nuclear power may have been/is the most impactful to human life: energy versus war; restraint versus force; detente versus annihilation; rule of law versus rogue use... One can do the trade offs in perhaps more applicable sciences, for example: synthetic life forms; biological constructs; chemical engineering et al. We live in a never ending cauldron of possibilities where all outcomes increasingly exist as a result of human ingenuity. The rule of law and our moral codes are the only binding principles that the community can foster to fundamentally shape human will. If there is a need for new laws then do so with factual education, public debate and openness centered around a health priority of "for the people" being paramount. However, competitive currents in science run deep today and as such active participation with guidelines would seem the only logical course. 

If there were publicly exposed real life cases where germ line modification would alleviate suffering & disease in newborn children then I would recommend that be shared as widely as possible. Certain neurological diseases have been mentioned - if germline science is the only way forward in some of these cases it's important to publicly state that & make it clear why. These and other indications may very well be the first cases where there is a real need to use germline/embryo editing, however somatic cell gene therapy is without doubt the immediate and overwhelming priority. 

I sketch below a fictitious scenario whereby a family has no choice, unless assisted by science - would it be ethical and morally correct to deny them their human rights to bear healthy children, should a technology be available to solve their case?

What happens when a known gene mutation is detected in an IVF embryo to a family with a genetic mutation history? Choice & hope drove them to look to protect against the very real & terrible consequence of giving birth to a child that will only suffer and die. If they didn't choose IVF fertility they would have no ability to protect the health of their child. God to them doesn't mean accepting a cruel and unjust outcome that imposes suffering on an innocent if there is an alternative. Don't implant that embryo and select/create more embryos until there is one which doesn't have the mutation? Is that acceptable to those that oppose IVF supernumerary embryo creation? What happens when all the created IVF embryos have the mutations? Don't implant any and send the couple home without solving their problem at considerable cost and emotional stress? Is that ethical? 

What happens when the Docs find a potentially suitable IVF embryo but advise that there is a risk that the couple faces that the disease could manifest itself anyway without complete replacement of the relevant DNA strands? Implant without a DNA edit and hope for the best? Try to detect any malformation issues during fetal development? Then what? Fetal intervention? If that's not possible? Try to solve any postnatal genetic issues with best efforts? What if it's too late for any real chance to help and the child is effectively DOA or critical beyond hope and cannot be expected to regain near normal function even with the most advanced modern treatment at the cellular level? Don't risk it? 




This on the other hand is not fiction. My brother has a seemingly healthy young 7 yr old son but the child's siblings weren't so lucky. Both were taken to full term, delivered and died. My sister-in-law had excellent medical care and after the loss of the first child, within days of birth, was monitored constantly throughout the 2nd & 3rd pregnancies. Her second child was again naturally conceived and made it through the gauntlet. The 3rd child died weeks after being born "healthy" & welcomed home into the family. They have suffered immensely and you can sense their deep sadness but they have joy & love in their hearts with the one that survived. We pray that little chap makes it all the way but if there were a way to screen the germline of his parents they may not have needed to play Russian roulette. In hindsight and with use of today's technology who would in their right mind try to conceive naturally knowing there was a significant risk, especially after having a previous issue? If a fatal brain disorder could go undetected in today's system and manifest itself in 2 out of 3 full term pregnancies then there is a real need to improve the process. Genetics presents the best hope to protect against such outcomes and it must be taken forward for all families. Parents to be should seek basic genetic testing and those at most risk must be offered IVF & advanced screening as standard. Informed decisions can be made once the available options are presented by the medical experts. If at some point in the future the process includes safe interventional genetics to assist life in being born healthily then I favor presenting such a choice to would be parents, if science has made it possible.   

The parents of tomorrow are ultimately responsible for the next generations and therefore should be considered with weight, as with those that have direct experience in the diseases for which this germline technology would apply, if any. I don't believe shock is an emotion the youth of today exhibit when presented with the technology of tomorrow. Rather it would be a shock to all if the very real images of affected children were associated with political inaction to cure, if there was a chance to avoid such pain & suffering.

Having said that the entire field of somatic genetics and cellular therapeutics is just emerging and needs to be the focus to establish itself prior to more advanced possibilities taking over the headlines. The media feed off controversy so it's best to find a way to agree than to publicly disagree, for the sector.

Once the intervention technologies are sound the medical community has an obligation, if not a legal duty, to present the options. In time once the public are familiar with the detection technology their acceptance of the more complex interventional options will become less futuristic and ethically questioned, in those cases where the only guarantee is germ line modification. 

Genetics holds enormous promise, as do potent cellular therapeutics. The union of the two, and their by-products, will be a powerful force for good. Early detection, intervention and eventually genetic modifications will be the key to freeing humans from their own frailties, which if managed as a universal community goal will serve rather than enslave generations to come. This future must be controlled and accessible to all.

For the moment though I can't see any reason whatsoever to accept personalized genetic enhancements nor use germline technology, if proven safe, beyond the absolute required need. Intervention to eliminate any possibility of irreversible disease, when a couple has no opinion, is where science can help bear a healthy child free of fatal developmental mutations. 

Perhaps in time there will be safe cost effective universal "vaccine" like concepts that edit our DNA in order to eradicate disease, strengthen our physical constructs, enhance our immune systems and extend our cellular longevity. A legacy any generation would envy... That would be a world worth imagining into existence - along with some other wish list items! 



Advocacy for cures.

Cheers


References:
MIT Gene Editing Article
PaulK Blog Interview with Dr. George Church
ARM Moratorium Request
ISSCR Guidance Statement
Genetic Scientists Policy Recommendations (pay walled)
Universal Declaration on the Human Genome & Human Rights - UNESCO
NIH Bioethics Resource


The Hemangioblast Progeny - Ocata's Blood, Immune & Cancer Programs

When we speak of the various programs Ocata has in development, apart from the Eye, they are referred to as "other" and are separated into boxes so the general targets become clearer - Blood, Immune & Cancer.

However, it important to understand that all these "others," and their various derivative relations, are based off of the Hemangioblast cell state precursor... i.e. eImmune Modulation using MSCs, eCancer Targeting using Dendritic/NK cells & eBlood Repair using Platelets, all via Ocata's Non-Destructive hESC Platform source or from any of the alternative Pluripotent Platform technologies (i.e. iPS, Parthenogenesis, SCNT).

Tissue engineering (organs) isn't yet in the preclinical phase at Ocata but could of course be a focus of research and product development/IP licensing if the company opts to push forward in that direction down the line with Pluripotent cells, most likely with Autologous reprogrammed cells using iPS, Parthenogenesis or SCNT Pluripotent sources.

For now it's the Allogeneic Hemangioblast offspring and as such all discussions in Blood, MSC/Immune, Cancer should be considered in relation to this when reviewing what the opportunity is for product development.

A program for engineered eDendritic cells targeting a pathogenic or virus strain can be separated from an engineered eDendritic cell deal for a Cancer indication - both derived from a Patented Pluripotent eDendritic cell IP rights chain that goes back three Patent layers to source. However, on top of those source IP rights is the engineered cell product itself (synthetic Product Claim) which will be the Exclusive Product License.

Is it more beneficial to break-up IP than outright License it wholesale per cell type? Will this occur When and If unique synthetic versions can be developed to optimize & uniquely address target market indications? For example why License the entire Cancer market to one partner when there are multiple potential partners in the space? Granted a potential Partner may address a cross-section of the space but one Partner may only be interested in or dominate in a few disease areas while others may be active in unrelated diseases and so forth... Each can have a tailored product using exclusive IP from cell origin to intermediate cell states to final proprietary formulation...

This is the strategic design for securing multiple partnerships to Ocata's underlying Platform & Program IP.

It is the unique or synthetic nature of the final product for distinct targets that will exponentially and dramatically expand the scope of collaborative understanding with Industry players.

The explosion in awareness and movement in cellular targeting via synthetic biology is the beginning of the paradigm shift in medicine.
        
CAR-T has been a research focus for a couple of years ago now - which was a welcome adjunct to an on-again off-again research effort on immunity, genetics & gene editing technologies. The nature of beating disease by way of empowering & harnessing the immune/blood system is fundamental to next generation therapies. Emily was one such proof many had been hoping for. Not that pure cells themselves or synthetic editing aren't invaluable in their own right to fight disease, but that complex modified biological cell constructs are possible as future effective treatments.

As with all cell treatments the ability to manufacture an inexhaustible supply of a replicable standard as an off-the-shelf product is what will separate the mass market offering from the targeted niche. The cell progeny differentiated to a terminal state and used in therapeutics worldwide is akin to a small molecule drug produced on an assembly line.

Autologous treatments against Cancer may be required when specific and unique disease states & expression patterns apply and will therefore require bespoke cellular targeting. However, in the broader market a product with replicable standards, cost & scale will be vital and sought after by way of Allogeneic product methodologies. 

Some Allo programs already exist based on adult cell sources however when the inherent expression benefits of Pluripotent derived cell factories are combined with synthetic multi-target gene edits and/or pathway modifications the final product becomes naturally more effective and valuable, in addition to the replicable conformity & economies of scale benefits. 

Allogeneic product isn't by itself the definition of a complete solution purely because it's from an immortal source & is replicable to a standard but it is when combined with the inherently more potent properties of early cell state gene expression and enhanced synthetic action/targeting... 

Product is the goal and when next gen product is available early prototypes, niche offerings & more costly general alternatives will be mooted.

Profitability models favor a wider adoption formula for acute, unmet and orphan diseases where there is no effective standard of care. Pricing will vary depending on volumes.

Repeat treatment requirements are yet to be determined in many cases for cellular therapies and may factor in to longer term chronic care maintenance, more in line with existing treatment options.  

The science is on the cusp of having a solid fighting chance against disease, trauma & degeneration. That is perhaps something I wouldn't have said only a few years ago. However, doubt is gone in my mind and only time is left to answer what will be the optimal mechanism to defeat each target. Knowledge is expanding exponentially and as a result I imagine within a relatively short period of time the majority of our molecular pathways and stepwise complexities of action and reaction within our cellular communities will be known.

There is a race on that has only one possible ending - the complete and total banking of knowledge of the biological process map of our physical selves.

Just as The Human Genome Project opened the doors to a world of new discoveries, the uncovered realities of cellular based mechanisms are paving the way for fundamental changes in our societies that will impact the very nature of how we live our lives. Once disease is tamed our planet will turn to sustainability to maximize the efforts of our new longevity. The full cycle may take a generation or two to occur but it is inevitable and beginning now.

Ocata is one of the many at the forefront of this new dawn, contributing with knowledge & potential. Their unique understanding, developmental expertise, early cell state technology, IP positioning and mission is what sets them apart as a sector leader and underscores what the opportunity represents as a whole.

Cheers

Creation, Ensoulment, Birth & The Ethical Use of a Donated Cell

School of Athens” by Rafael w/ Plato and Aristotle - referred to by
Pope Francis during EU Parliamentary address Nov 25, 2014
There is a bridge between the opinions that divide us on this subject. I have written a number of times on the Middle Way, a Compromise if you will, that will heal the scar and abate the fear.

There is an ethically sound scientific process to allow for a donated Pluripotent stem cell from Human pre-embryos to be used for medicine.

The cellular process of embryogenesis has been studied at great length. The fundamental origin of Human Life is indeed the Creation of a pre-embryo – that Sperm and Egg moment and the days thereafter of cell preparation for a Mother’s acceptance. This fertilization moment and the immediate cell divisions after are central to the beginnings of Healthy Physical Life. This understanding is universally acknowledged.

The success of that biological union in the combination of DNA from both parental sexes (male & female) provides the early catalytic events that set in motion the journey to deliver a full term baby. The process is clearly not perfect by anyone’s measure and doesn’t at all guarantee stepwise progress nor a healthy outcome. There are a number of important & vital moments along the way – most importantly to all is the Mother’s acceptance of the pre-embryo into her uterus via the Implantation process around Day 8 or 9 post fertilization.

The period before Implantation is referred to as the “pre-embryo” phase, as it is clear from the scientific evidence and analysis that the cellular process of developmental Life isn't sufficiently complete to begin the formation phase of Human Life unless these early individual cells develop to the Blastocyst stage, are accepted and successfully embedded in the uterus wall of the Mother. Unless that happens a woman will pass the pre-embryo cells out of her system, as she does with the uterus walls during her monthly period cycle. Some women never accept a pre-embryo into their uterus as a result of many possible problems, including the genetic instability or malformation of the combined DNA nucleuses. Some women can only conceive with IVF assistance and pre-embryo screening help.

IVF is not the topic here so I will leave that for others to continue to debate its validity as this blog article is in reference to the pre-embryo period and the possible non-destructive removal of a single cell during this post-fertilization phase prior to Implantation.

Fertilization and the pre-embryo period is a starting cycle without which Human Life couldn't develop, yet it is still merely a starting signal for the remaining many phases that will confirm and define what it is to Be Human.

The scientific distinction is as clear as an Egg and Sperm. A pre-embryo is the union of DNA strands ready to embark on the journey to create a Human. A ball of intelligent cells pre-programmed to develop if the formation is correct, the proper signals received and the internal script processed successfully. An embryo is the resultant accepted & developing Lifeform once embedded in the Mother’s uterus. A Fetus is an established growing person with a beating heart and developing brain within the Mother’s womb. These stages of Life are clearly delineated by the process itself. Science merely exposed what Nature has already defined. The success ratio of Nature is nowhere near perfect in this process, as naturally fertilized ovums are discarded regularly and assisted conception ratios low.

What is important to note here is the difference between a pre-embryo, an embryo and an Human Fetus.

Needless to say all stages are Life and should be duly respected.

Healthy Human Life can and does develop from a pre-embryo after one cell is extracted for analysis and medically screened while the remaining pre-embryo cells continue to divide and develop. The same biological process is required for all pre-embryos to be accepted into and nurtured by the Mother’s uterus – including the one that had a cell extracted for genetic screening. Healthy babies are born every day using various cell extraction screening techniques, free of genetic issues as a result.

The confusion here is that during these past years of discovery cells were used from leftover & donated pre-embryos that were not needed any longer by couples that had fertility treatment to conceive. These pre-embryos were donated and had their cells removed in a process which terminated the pre-embryo’s development. This method of obtaining cells via donated pre-embryos for science continues. This method of cell extraction isn't necessary as a cell can be extracted from an earlier stage pre-embryo using a technique called Preimplantation Genetic Diagnosis (PGD), which is used daily by fertility clinics world-wide. It can and should be used as the method of choice to extract a Pluripotent cell from a pre-embryo in order to screen for genetic issues while also enabling the process of scientific discovery & cellular science. A Pluripotent cell is not a pre-embryo nor is it capable of developing to become a pre-embryo or embryo. The use of this PGD process can & does maintain the integrity of the pre-embryo state and it’s potential, while allowing for genetic screening & vital treatments for those that suffer from disease. One does not negate the other.

While I can appreciate the moral dilemma with respect to those that feel a pre-embryo is a Human Life, I must differ in that the science has proven that Human Life isn’t yet defined in these cells. There is Biological Life of course present and the potential to develop further into a Human but it isn’t sure whether it may or may not have the integrity to be viable nor capacity to develop further. It isn't sure either that the Mother’s system will accept the pre-embryo into her uterus and begin the developmental process of formation to become what is defined by all as being Human. This process is dependent on a number of natural system checks and balances. It has been revealed that a successful pre-embryo must first properly create a DNA construct and divide correctly to the point of being presentable to the Mother’s uterus. Incorrectly formed pre-embryos don’t, in almost all cases, pass this initial test. To say that an incorrectly formed pre-embryo that is rejected by the Mother’s system is a Human is wrong. This would by extension apply also to a pre-embryo that seems to have the right cellular makeup but still doesn't get accepted by the Mother’s uterus for other natural selection reasons. There are chemical signals within the Mother’s body that function as a viability filter and She initiates acceptance & provides the signal environment for Human organ development post Implantation. So unless a pre-embryo embeds in the uterus we cannot begin to be classified as Human as we haven’t started to emerge from that pre-embryo ball of cells and take shape. Even then the issue of the many and correctly passaged development stages of the embryo into a Fetus lies ahead.

Our Churches, Temples & Shrines aren't the sole purveyors of ethics and moral standing in our community. They certainly can help us along the path but we must all accept our own responsibility to understand and draw conclusions on the reality of our progress as a society. If Religion is anything it is a bellwether for the community and when some within the community need its guidance it has a duty to inform and guide based on the best interests of the people themselves, by disseminating knowledge and wisdom in a practical and spiritual context.

I say this as it has long been debated whether pre-embryo cells from donated IVF fertility treatments are sound ethical starting blocks for medical science. Will this still be the case when the truth is known that pre-embryos need not be destroyed and their potential maintained?

It is my opinion that to negate the progress of medical science in assisting the creation of Life is tantamount to ignoring Man in their quest for Love & Happiness. Especially if it doesn't harm the potential of further Life becoming a reality. It is also important to acknowledge that while assisting Life science has opened a door for simultaneous treatment of the sick. Life and Treatments together in one, as God intended.

Will there be criticism when medical science proves that Mother Natures’ most important cells – the potential Life forming pre-embryo cells – are used for the living that suffer and provide needed relief? Or will the misunderstood concept of the need to destroy prevail while the true facts of early Life processes, the nature of an independent cell state & its developmental knowledge be withheld from God’s people?

Pre-embryo cells can be taken without harm to the potential of Life and donated to help the living. Tissue willingly provided, as is done regularly today with blood and organs. A child can be born only when a pre-embryo is accepted by a Mother’s uterus, develops and successfully grows to term.




A day 3-4 Morula stage cell extraction does not destroy the potential to create Life. 
Later stage cell extractions at the Blastocyst Stage terminates the pre-embryo.
 
Ensoulment is by a far the greatest gift to Human Life – for without it we would be unconscious. Consciousness defines our Personhood, our Self. It is the defining characteristic that allows the physical to exist and the non-physical to be reasoned. One could say that this component of Humanity is Divine. It certainly is one of the central tenets of Religion and for which a valued guide in our community is sought.

Throughout the History of Christianity there has been an overriding concept debated within the inner halls of the Institution itself – Ensoulment and when it occurs.

More clearly than ever today is the molecular insight into the developmental phases of the origins of Human Life. This in itself requires the ethical and moral concepts of the day to be reflected upon.

Terminating a pregnancy – once it is established in the Mother’s womb – has always been an immoral act in the eyes of the Christian Church. In certain circumstances the willful termination of a developing Life was considered unavoidable if the Life of the Mother was at risk. The implications of this Human Act in the eyes of the Catholic Church was Excommunication as the punishment, in most cases. However, this was not universally true throughout history as there was a clear separation between the ethics of the immoral act of terminating a Life willfully and the punishment itself, if it was performed early in the developmental cycle post fertilization.

It seems the “Ensoulment” moment was the dividing line. A uniformly accepted believe for most of recorded history as occurring after a period of weeks post fertilization. Therefore the doctrine of a Human Life’s relationship to God, beyond the potential of a developing Lifeform, was enshrined in the Church’s teachings in this fundamental Ensoulment moment. These philosophical discussions within the Catholic Church are a documented series of changing positions dating back to the beginnings of the Christian Church.

When the issue was debated it was framed by the obvious question of at what point in the development of a Life in the Mother´s womb is that Life considered Human with a Soul and therefore one with God.

That Ensoulment moment was long considered 40 days after fertilization at a minimum for a male Fetus and 90 days at the outside for a female Fetus. The documentation dates back thousands of years to the Ancient Greek scholars & Aristotle in 350 BC. However, even at that time there were contradictory opinions that held the Soul entered at the moment of conception. The teachings of Aristotle of a later Ensoulment moment became widespread by the time of Augustine in the fifth century as the concept of stage development of a Lifeform from vegetative to animal to Human became accepted. Prevailing Christian thought became documented in the 12th century by the preachings of Thomas Aquinas and the Council of Vienne to that of Aristotle. Yet subsequent Popes differed on the doctrine of excommunication on the basis of formed versus unformed Fetuses and the topic of Ensoulment as a consequence. Early Church theologians attempted to bridge this divide with a Casuistry compromise that allowed for non-ensouled Life to be regarded as different than that of an ensouled Human Life. Since the eighteenth century the Church has considered Human Life beginning at conception along with Ensoulment. Needless to say this debate has raged in the Church since it’s inception as an Institution.

What is apparent from a lay perspective is that the Church has adapted its own views to the popular reality of the day and considered scientific facts, as presented. The difference between then and now is fundamental in that today there is molecular science and it has revealed to all the embryonic process and the value of the cell in curing the living.

As the reality of the day becomes the norm, there is and will be assisted births, genetic treatments and cellular science derived from the earliest stage of Life (naturally conceived, programmed or reprogrammed). An altered series of biological interventions by science in the process of serving his fellow man.

This process can be done without destroying a naturally fertilized union between an Egg and Sperm. There are many ways to create that don’t destroy. There is a need to accept and understand what the difference is between the viability to create Life, the potential of cells and Human Life itself. Without bridging the divide on the issues a meaningful opportunity to engage and grow stronger together will be lost.

There is no question in my mind that there is a Duty in respecting existing and developing Human Life Implanted, Developing & Ensouled in the womb through all possible means.

Medical assistance by way of Non-Destructive cell science for the benefit of those in need is similarly a Duty and Humane.


Blood & The Search For A Universal Drug Delivery System

The doctrine that we are all equal under God applies in reality to the very Blood of humanity that runs through our veins. This was the shocking truth that changed an age old way of intellectual & class division. After millennia Science did that not faith. The fluid of life is an interchangeable commodity that drives the body and mind. A genetic brain unique to a person's cells is common enough to be of practical benefit. Donors of all types, colors and creeds can have some siphoned off and provided to those that need a refill. 

We accept the DNA of another to live on, with new Blood, without question and without any harm.

With 7.2 Billion humans on the planet you would think that we'd have enough of the Red stuff to go around. Think again. We don't even have enough fresh supplies to meet current demand, let alone future requirements based on the donation system. How can we expect this system to suddenly change to meet the forecasted demand when the population hits 10 Billion within a few decades and then 15 Billion a generation or two later?

Enter science, as usual, to solve the human evolutionary dilemma - Create it.

Not only is it possible to do so now, in inexhaustible volumes to satisfy all, but those cell products can and will be modified by the Scientists & Doctors of this 2nd Blood Revolution to deliver the needed solutions against the parasites, funguses, viruses, bacterias et al. that plague & kill daily in countless numbers.

Engineered weapons of the vascular system that naturally hone in and destroy invading pathogens.

The below provides a rough summary of how this is coming together from the perspective of ACTC and it's scientific colleagues.

Cheers

Phase 1 - Blastomere Derived Renewable Stem Cell Line
Phase 2a - Clinical Expansion & Banking of Hemangioblast Derived Megakaryocytes
Phase 2b - Engineered Variants for Drug Delivery Requirements
Phase 3a - Differentiation of Platelets, Red Blood Cells & Line Derivatives 
Phase 4a - Biocompatible Unit Preparation & Universal Distribution
Phase 4b - Locally Served Fresh Product via Bioreactor Automated Production

________________________________________

REFERENCES:

Cell Research Jan 2011 - "Platelets generated from human embryonic stem cells are functional in vitro and in the microcirculation of living mice" - SCRMI, Univ of Illinois Chicago, Cha Univ, Harvard / BWH & ACTC 

Blood July 2014 - "Platelet bioreactor-on-a-chip" - Harvard / BWH, Univ Colorado & Colorado School of Mines, McGill, ACTC

Vector - Boston Children's Hospital Blog March 2014 - "The Platelet Whisperers

MedCity News April 2014 - "Biochip mimics how the body produces platelets so they could be made in a lab"


NY Times May 2014 - "Young Blood May Hold Key to Reversing Aging"

UCSF July 2014 - "Key to Aging Immune System Is Discovered

Proceedings of the National Academy of Sciences of the USA, June 2014 - Whitehead Institute & MIT - "Engineered red blood cells as carriers for systemic delivery of a wide array of functional probes"

The Scientist Sept 2014 - "Next Generation: Blood-Cleansing Device" - (Engineered MBL Protein use example in fighting Sepsis - with cell engineering it can be done without dialysis)



Advanced Cell Technology's Scientific Advisory Board

Dr. Langer's Lab & Dr. Jensen's Lab of MIT

The Scientist July 2013 - "Narrow Straits - Transfecting molecules into cells is as easy as one, two, squeeze.

Proceedings of the National Academy of Sciences of the USA, Feb 2013 - "A vector-free microfluidic platform for intracellular delivery"

R&D, July 2013 - "Researchers put squeeze on cells to deliver"

Dr. Daley's Lab - "Hematopoiesis Research" - HHMI / Children's Hospital Boston / Havard  & "CellNet" - Children's Hospital Boston / Havard / Boston Univ & iPS mRNA Tech

Daley / Children's Hospital Boston / Harvard Patent Families: 

Biomechanical Induction of Hematopoiesis
Inhibition and Enhancement of Reprogramming by Chromatin Modifying Enzymes
Methods for Enhancing Hematopoietic Progenitor Cell Engraftment 
Method to Produce Induced Pluripotent Stem (iPS) Cells from Non-Embryonic Human Cells 
Method of Enhancing Proliferation and/or Hematopoietic Differentiation of Stem Cells
________________________________________

Advanced Cell Technology's Patent Portfolio for the Blood Program:

INEXHAUSTIBLE SOURCE OF RENEWABLE STEM CELLS:

Blastomere Non-Destructive Human Embryonic Stem Cell Technology 

Blastomere Patent Family

5 Granted US Patents: 1, 2, 3, 4, 5

iPS/Reprogramming Renewable Stem Cell Derivation papers 1 & 2

iPS/Reprogramming Renewable Stem Cell Patent Family Portfolio: 1, 2 with examples A, B, C and SCNT Tech

EARLIEST YOUTHFUL BLOOD LINE POSSIBLE

HEMANGIO-COLONY FORMING CELLS - US Patent Granted & Patent Family 

HEMANGIO COLONY FORMING CELLS AND NON-ENGRAFTING HEMANGIO CELLS - App Pub March 2011 & Patent Family 

UNIQUE BLOOD LINE CELL PRODIGY DERIVATION:

(WO2011069127) LARGE SCALE GENERATION OF FUNCTIONAL MEGAKARYOCYTES AND PLATELETS FROM HUMAN EMBRYONIC 
STEM CELLS UNDER STROMAL-FREE CONDITIONS - PCT Pub June 2011 & US App Pub Dec 2012 & Patent Family  
(Note: SCRMI is a JV between ACTC & Cha Biotech of Korea - North American Rights belong to ACTC - Japan/Korea to Cha - ROW split)

(WO2014100779) METHODS FOR PRODUCTION OF PLATELETS FROM PLURIPOTENT STEM CELLS AND COMPOSITIONS THEREOF - PCT Pub June 2014 & US App Pub Sept 2014

Synthetic Biology & Process vrs Product - is this the Stem Cell sector's next big commercialization challenge?

It has been ruled on by the Supreme Court and Affirmed in Federal Appeals Court and at the USPTO that naturally occurring biological matter cannot be exclusively owned. This was today confirmed again in the matter of Roslin Institute's desire to Patent the "clones" of their SCNT cloning process. After years of examination rulings and a lengthy legal challenge, the Federal Appeals court upheld the decision of the USPTO that no Patents will be issued on the product of the process that created Dolly, as it produced a copy of a nature, and therefore "Dolly's genetic identity to her donor parent renders her unpatentable." Further, Judge Dyk stated that "There is nothing in the claims...that suggests that the clones are distinct in any relevant way from the donor animals of which they are copies."

The issue at hand is pertinent and important to note in that cells themselves are natural biological products, aren't they? Therefore they themselves, if unaltered scientifically, wouldn't be Patentable themselves therefore. The Process yes but the cell itself, if identical to the naturally occurring original, wouldn't?

Processes in the stem cell field are seemingly never ending...

The "product-by-process" standards that have applied to determining patentability by limiting duplicate product patents will need to be revisited to narrow the "product" window to only unique synthetic constructs. This developing legal framework of patent scope now calls into question old technology product claims and may give rise to a freedom to operate latitude the Courts are indicating on natural biological ownership.... or am I missing something here?

Are cells which are innovatively derived also being pushed to be genetically altered as a synthetic variant of the original as a requirement to secure a firm path to market?

Is an RPE cell derived from different innovative methods, such as hESC, iPS, SCNT, hpESCs, subject to a novelty test against an existing natural RPE cell in order to secure product claims? Will there be a race to alter the cells to create genetically unique versions in relation to the natural standard and the competitive versions?

Cheers  

__________________

Dolly the Sheep-type clones ineligible for patent: appeals court
BY BERNARD VAUGHAN - Thu May 8, 2014 6:45pm EDT

(Reuters) - The method for cloning animals such as the famed Dolly the Sheep can be patented, but the resulting animals themselves cannot, a U.S. federal appeals court has ruled.

"Dolly's genetic identity to her donor parent renders her unpatentable," Judge Timothy Dyk wrote Thursday for the U.S. Court of Appeals for the Federal Circuit in Washington, D.C.

Pilar Ossorio, a professor of law and bioethics at the University of Wisconsin Law School, called the decision a victory for people who thought cloning animals was morally wrong.

"This ruling is taking away an incentive for research organizations to pursue more research into cloning, at least on the margins," she said.

Scientists Ian Wilmut and Keith Campbell of the Roslin Institute of Edinburgh, Scotland, generated international headlines and intense ethical debates in 1996 when they created Dolly the Sheep, the first mammal to be cloned from an adult cell.

Dolly, named after country singer Dolly Parton, was euthanized six years later after she was diagnosed with a progressive lung disease.

The institute, which owns a patent to a method of cloning called somatic cell nuclear transfer, applied for a patent over the clones themselves but was rejected by a U.S. Patent and Trademark Office examiner in 2008.

In February 2013, the USPTO affirmed the examiner's decision, saying the clones did not possess "markedly different characteristics than any found in nature."

In affirming the USPTO, the Federal Circuit said that nature, natural phenomena and abstract ideas were not eligible for patent protection.

Salvatore Arrigo, a lawyer for Roslin, said he was disappointed with the ruling.

"There's no doubt in anyone's mind that Dolly is man-made," he said.

Roslin had argued that its clones were distinguishable from their donor mammals, in part because environmental factors could make their shape, size, color and behaviors different than their donors.

The Federal Circuit disagreed, noting that Roslin itself had said that such differences were produced "quite independently of any effort of the patentee."

"There is nothing in the claims...that suggests that the clones are distinct in any relevant way from the donor animals of which they are copies," Dyk wrote.

The USPTO declined to comment.

The case is In re Roslin Institute (Edinburgh), U.S. Court of Appeals for the Federal Circuit, No. 1407.

http://www.reuters.com/article/2014/05/08/us-ip-dollysheep-idUSKBN0DO1ON20140508

Pluripotent Stem Cells - OCATA's Broad Scientific Positioning

Stem cell science is inherently complex as it relates to biological systems which are only now becoming fully explored and understood. To many Stem Cell Therapeutics is new but in reality Bone Marrow (BM) transplants pioneered the sector over 40 years ago and the use of BM stem cells has been widely adopted throughout the world since then. Thus the sectors' Adult Stem Cells' origins led investigators to first develop more specific cell types for Adult Stem Cell Therapeutics, such as Adult Mesenchymal Stem Cells (MSCs) and terminal cell types of Adult MSC progenitor origin, such as Skin and Cartilage et al, which have been approved as the first purified and expanded Stem Cell Products available Internationally. To round out the background, importantly during this period James Thompson discovered a protocol to isolate, maintain and grow Human Embryonic Stem Cells (hESCs) in 1998 and the field opened up to the possibilities of using nature's master cells which are able to create any cell type in the body - i.e. a Pluripotent Cell - which Adult cells can't do. Also the potency and replicative power of these cells made hESC Therapeutics a viable cost effective medicinal option, which was therefore pursued by many in parallel to the work being done on Adult Stem Cells.

Now Pluripotent cells can be created from iPS and hESC technologies, as well as SCNT and Parthenogenesis. Adult Stem Cell researchers have also discovered recently a couple of potential sources of Pluripotent cells - Very Small Embryonic Like (VSELs) and Wisdom Tooth Dental Pulp (DPPSC) - and are investigating their capabilities. The nature of Pluripotency is important to grasp as the literature refers to Pluripotency as a general state, which also can be described as "embryonic" - however it doesn't necessarily mean derived from an Embryo, as the foregoing technologies prove. Ocata Therapeutics' (formerly Advanced Cell Technology "ACTC") historical work was to create "embryonic" cells by means of whatever technology was stable enough to generate viable Pluripotent cells... This work included extracting cells from an early stage fertilized human egg (human Embryonics - eventually Blastomere IP), from the false fertilization of a human egg, which cannot become a human (Parthenogenesis IP), from the transfer of an adult cell's nucleus to a human egg with fusion (SCNT or "Therapeutic Cloning" IP), from the reprogramming of an adult cell back in time to a Pluripotent state (De-differentiation IP - now called iPS)... Further to this OCATA was experimenting in those early days also with Trans-Differentiation, which is the reprogramming of an adult cell to directly become another adult cell type without reversing back to an intermediate Pluripotent state (Trans-differentiation IP). This early work was late 1990s to early 2000s...

As mentioned the term Pluripotency is by definition the ability to derive stem cells of any type. The Technology IP in the sector is how to create Pluripotent cells and then also how to maintain and differentiate those Pluripotent cells into the desired cell types and then scale those sufficient for Therapeutic marketing at a reasonable cost... As an analogy think of this as a Tree with a few Roots only that feed a Trunk - the Trunk is the Pluripotent state from which there emerges a number of Branches, which represent the Multipotent states, which then sprout Sub-Branches and then the leaf bearing Offshoots of those which produce the Leaves.... These Leaves are the finished individual cell types.. This is where the analogy breaks down somewhat as the Main Branches in the Tree, the Sub-Branches, the Offshoots and the Leaves would all be different colors representing different states along the unique path to the final cell types, nor does it represent the accurate number of possible intermediate step stages to get to the end result Cell Type - anyway you get the point I hope..

Human Embryonic Pluripotent Cells (hESCs) can be made by anyone soon given Thompson's WARF hESC derivation process is coming out of Patent Protection. That will open up hESC science to more innovation and programs - but it is a destructive process. In Europe the WARF Patents were cancelled and therefore the hESC research field was pursued with more interest than it was in the US. As everyone knows OCATA invented a unique approach to derive an hESC by way of a non-destructive process - Blastomere IP. That is what sets OCATA apart in getting to the Pluripotent Trunk stage using the embryo Root. No one else does that and Ocata have a Patent in the US and Patent Applications submitted in other Territories to protect that hESC advantage. In Europe a non-destructive technology is required to pursue Patentability - OCATA awaits the European Legal process on its Blastomere Patent Application to secure its rights there. This is apart from the differentiation IP protocols of taking a Pluripotent cell and making it differentiate into a number of different Multipotent cell lineages and end cell types. These are what ACTC has a unique Priority based ability to develop and is pursuing broad Patent IP on for the Eye, Blood and Immune System areas... This positioning is unique in the world of hESC science for those areas of development IMO.

In respect to iPS Ocata is looking to secure the "Pluripotent" definition inclusion in their more recent Patent Extension Applications in all the above program areas as a right from the Original Filings and the inclusive Legal interpretation of the term "embryonic" in recent rulings. This has already been established in Australia for the Eye Program. The term iPS is a term coined by Yamanaka and as I relayed refers to taking an Adult Cell and converting it with reprogramming steps to a Pluripotent state - this is another of the Roots of the Tree Trunk. OCATA and others were doing this long before Yamanaka - OCATA's term for that was "De-differentiation" and the components of that technology are Patent Filings with v.early Priority Dates (late 1990s and early 2000s). A number of Patent Filings relate and ref to OCT4 as a differentiation / reprogramming protein used in the technological processes and methods that ACTC and others were experimenting with. In 2006 Yamanaka defined a set of 4 factors (incl. OCT4) that if used according to his protocol would convert Adult Cells back to a Pluripotent state. The fact that he documented and published this protocol in the Literature and made it widely available as a process for Lab Researchers made it a "standard" and won him the Nobel (rightly so). However, it doesn't negate the fact that other scientists had been working on the same reprogramming language, some way before Yamanaka (incl. OCATA). This is what Mgt. have been saying and that it has an early Priority on the use of OCT4 in the science. This of course relates to those using OCT4 in their protocols for iPS - however, it is an evolving field so the use of OCT4 in certain Protocols isn't necessary... I've stated my opinion on OCT4 in this iCell Thread.

Gary Rabin, then CEO of OCATA, relayed in an interview that OCATA's iPS approach was "zero-footprint reprogramming using vectorless technology" and is more to the point here as it's a reference to the difference in approaches being played out in the iPS field currently... Rather than getting caught up in defending the OCT4 Priority - which IMO Big Pharma partners will do later, if necessary - the current issue is how well do the various protocol approaches perform... That is still an open question but certainly I think most would agree now that an integration free route (i.e. not entering the genome) is safer - hence the effort to use steps that avoid integrating. However, the use of vectors (irrespective of Viral use or not) is also at issue here and it's been shown in certain cases to create residual effects. Yamanaka and Thompson use vectors. The leading safety protocols are the Harvard related iPS teams - Daley's mRNA process and Kim/OCATA's protein method... Safety first is the goal - hence the keen interest in Research Licenses for freely available integrating and non-integrating vector based iPS lines (Yamanaka and Thompson) but slow progress on Therapeutic Programs based on same... It is still too early to determine which Pluripotent route is best suited for mass market therapeutics but clearly OCATA is amongst the handful of leaders in the field and one could say is the frontrunner with it's safety first iPS protocol pending IND submission selecting an enucleated cell type (Platelets) as a further safety precaution. In addition, OCATA has a potential lock on the Pluripotent RPE derivation that the other front runner, Yamanaka, is pursuing as his first indication, which would add distance to OCATA's first mover position...

In summary OCATA's Pluripotent strategy is to link this fundamental Trunk source for cell derivations lineages for the Eye, Blood and MSC Programs. Apart from that the Pluripotent protocols are valuable as stand alone Root Platforms - Blastomere, iPS Protein Reprogramming, SCNT and Parthenogenesis. These foundational Root technology approaches, plus Trans-Differentiation tech, make up the knowledge base and IP of the company generally and are interwoven as part of its Scientific Tool Kit. The breadth of the science IP protects the company from sector challenges - even if it's not using a part of the technology IP vault for a specific program.... Patents granted are more valuable than Applications of course but in this field knowledge and innovation are the keys to success given it's moving so quickly - a first mover advantage with IP is a powerful force.

To conclude it has been said that "Ocata have some of the best developmental biologists in the world" and it's clear they have IP in all Pluripotent technological avenues and are pioneering the science with a first mover strategy in these Root processes, which therefore suggests that if any one process is successfully translated this will establish OCATA's future and those associated.

Cheers

Root Pluripotent Processes:



This video below of Dr. Lanza's scientific presentation goes into detail about the various steps mentioned in the summary above - note that the Doctor talks about all Root IP approaches as part of his scientific knowledge base toolkit (hESC, SCNT, iPS and by default Parthenogenesis when referring to the Egg - see below Patent App).


The Cytoplasm is nature's incubator. What Ocata have here is a foundational approach to reprogram an old adult cell backwards in time to be youthful via a young new Egg, along the way using technology to modify.. This effectively is the road to healthy longevity via a natural cell regression mechanism that uses you're own adult cells in further steps to generate pluripotent cells for therapeutics... Previously OCATA needed access to a constant supply of human eggs and therefore it wasn't viable - now it is. SCNT is the term used for this as it stands for Somatic Cell Nuclear Transfer and is now to be combined with OCATA's iPS and Parthenogenesis Platforms using ES culturing differentiation technology for patient specific cells and tissues as an alternative route to deliver Cell Therapeutics. Genetic modifications are part of the overall process generally...

Effectively this states that ACTC uses Eggs to nurture regression, then uses SCNT technology or Parthenogenesis to derive "embryonic" cells for Therapeutic use... Before the lack of human Eggs was the bottleneck and the ethical issues associated with creating human embryos. With this technology approach Ocata have choice and control over the entire process of developing Pluripotent cells without human fertilized embryos and without the possibility of viable embryo by products... iPS allows the reversion an Adult cell to become an Egg and with controlled stimulation "embryonic/Pluripotent" cells can be produced without any possibility of developing viable human embryos... This is Lanza's scientific stem cell tool kit brilliance and what makes OCATA unique in that it has ALL the necessary pieces of the puzzles and knows how to assemble them.

Further General References:

Embryonic stem cell - Wikipedia, the free encyclopedia
Induced pluripotent stem cell - Wikipedia, the free encyclopedia
Somatic-cell nuclear transfer - Wikipedia, the free encyclopedia
Parthenogenesis - Wikipedia, the free encyclopedia
Transdifferentiation - Wikipedia, the free encyclopedia
Adult stem cell - Wikipedia, the free encyclopedia (VSELs)

Added Dr. Zarbin's papers & presentation:
http://www.revophth.com/content/d/retina/c/37809/
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3176062/
http://www.asorn.org/client_data/fil...zarbin2012.pdf